Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

• Are ≥ 18 years of age by initiation of study treatment.

• Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL)

• Have measurable nodal disease

• Are willing to undergo lymph node biopsies or biopsies of other involved tissue

• Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists

• Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen

• Have a life expectancy of at least 12 weeks

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

• Have CD20+ malignancy

⁃ Have hematological and biochemical indices within prespecified ranges